今日药学

2020, v.30(12) 837-840+844

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

法匹拉韦治疗新型冠状病毒的应用评价与药学监护
Application Evaluation and Pharmaceutical Care of Favipiravir in COVID-19

洪晓冰;杨琛儿;杜佳虹;余泽林;符红波;陈杰;
HONG Xiaobing;YANG Chener;DU Jiahong;YU Zelin;FU Hongbo;CHEN Jie;Department of Pharmacy,The Second Affiliated Hospital of Shantou University of Medical College;Shantou University Medical College;Department of Pharmacy,The First Affiliated Hospital,Sun Yat-sen University;

摘要(Abstract):

法匹拉韦是一种新型广谱抗病毒药物,本文从法匹拉韦的药理作用与药代动力学特征、临床应用、治疗新型冠状病毒肺炎的理论依据进行分析和总结,为临床上应用法匹拉韦治疗新型冠状病毒肺炎的安全性及有效性提供参考,提出对不同人群给予合理用药和监护建议。法匹拉韦治疗新型冠状病毒肺炎有一定作用,其适应证、最佳使用剂量、特殊人群用药及联合用药上还需要更多的研究和探索。
Favipiravir is a new broad spectrum antiviral drug.This article illustrates theoretical foundation for the treatment of COVID-19 from pharmacological activity,pharmacokinetic characteristics,and clinical application.It provides reference for the safety and availability medication in clinical application of favipiravir to COVID-19 and summaries reasonable recommendation of favipiravir in therapy for different people.Favipiravir showed significantly treatment effects on COVID-19,but the indications,optimal dosage,drugs usage with special individuals and drug combination need more explorations.

关键词(KeyWords): 新型冠状病毒肺炎;法匹拉韦;抗病毒药物;合理用药;药学监护
COVID-19;favipiravir;antiviral drug;rational drug use;pharmaceutical care

Abstract:

Keywords:

基金项目(Foundation): 广东省医学科学技术研究基金项目(A2019154);; 汕头市医疗卫生科技计划项目(汕府科[2020]66号-23)

作者(Author): 洪晓冰;杨琛儿;杜佳虹;余泽林;符红波;陈杰;
HONG Xiaobing;YANG Chener;DU Jiahong;YU Zelin;FU Hongbo;CHEN Jie;Department of Pharmacy,The Second Affiliated Hospital of Shantou University of Medical College;Shantou University Medical College;Department of Pharmacy,The First Affiliated Hospital,Sun Yat-sen University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享